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Introduction
The serine/threonine phosphatase calcineurin (Cn) plays a main 
role in a wide variety of physiological and pathological pro-
cesses, including the immune response, neuronal plasticity, and 
cardiac development and hypertrophy (Schulz and Yutzey, 2004). 
In response to calcium increase, Cn induces dephosphorylation, 
nuclear translocation, and activation of the NFAT transcription 
factors, a process sensitive to the action of the immunosuppres-
sive drug cyclosporine-A (CsA). Cn enzymatic activity requires 
a catalytic (CnA) and a regulatory (CnB) subunit, variants of which 
are encoded by multiple genes (Hogan et al., 2003). The CnA 
subunit includes protein domains conferring catalytic activity, 
CnB interaction, calmodulin-binding and a C-terminal auto-
inhibitory domain, which blocks the catalytic site and is removed 
in response to calcium increase. Three CnA genes have been 
 described: CnAα and CnAβ are ubiquitously expressed, whereas 
CnAγ is restricted to brain and testis. Two CnAβ isoforms, 
CnAβ1 and CnAβ2, which differ in their C-terminal domain, are 
encoded by alternatively spliced transcripts (Guerini and Klee, 
1989). The typical autoinhibitory domain present in CnAβ2 and 
other CnA isoforms is absent from CnAβ1, in which an un-
related C-terminal domain is generated by the translation of 
intronic sequences (Fig. 1 A; and Fig. S1 A, available at http://www
.jcb.org/cgi/content/full/jcb.200704179/DC1). This novel domain 
is preserved in the CnAβ1 orthologues from different species 
(Fig. S1 B), especially in higher vertebrates, suggesting an evo-
lutionarily conserved role for this Cn variant.
In skeletal muscle, the Cn/NFAT pathway mediates myo-
tube differentiation, enhances myoblast recruitment, controls 
muscle fi  ber type specifi  cation, and ameliorates injury to dys-
trophic muscles (Friday et al., 2000; Naya et al., 2000; Horsley 
et al., 2001, 2003; Parsons et al., 2003; Stupka et al., 2006). The 
function of the CnAβ1 isoform has not been explored because 
no obvious phenotype was reported in a germline knockout of 
the CnAβ gene (Bueno et al., 2002). Notably, in that study the 
knockout scheme involved deletion of catalytic domain encoded 
by exon 2, which would still allow transcription of in-frame 
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T
he calcium-activated phosphatase calcineurin (Cn) 
transduces physiological signals through intracellu-
lar pathways to inﬂ  uence the expression of speciﬁ  c 
genes. Here, we characterize a naturally occurring splic-
ing variant of the CnAβ catalytic subunit (CnAβ1) in 
which the autoinhibitory domain that controls enzyme ac-
tivation is replaced with a unique C-terminal region. The 
CnAβ1 enzyme is constitutively active and dephosphory-
lates its NFAT target in a cyclosporine-resistant manner. 
CnAβ1 is highly expressed in proliferating myoblasts and 
regenerating skeletal muscle ﬁ  bers. In myoblasts, CnAβ1 
knockdown activates FoxO-regulated genes, reduces pro-
liferation, and induces myoblast differentiation. Conversely, 
CnAβ1 overexpression inhibits FoxO and prevents myo-
tube atrophy. Supplemental CnAβ1 transgene expression 
in skeletal muscle leads to enhanced regeneration, reduced 
scar formation, and accelerated resolution of inﬂ  ammation. 
This unique mode of action distinguishes the CnAβ1 iso-
form as a candidate for interventional strategies in muscle 
wasting treatment.
Correspondence to Nadia Rosenthal: rosenthal@embl-monterotondo.it
A. Paul’s present address is Novartis Institutes for BioMedical Research, 
Musculoskeletal Diseases, 100 Technology Square, Cambridge, MA 02139.
Abbreviations used in this paper: Cn, calcineurin; CnA, calcineurin A; CnAα* 
and CnAβ*, artiﬁ  cially truncated forms of CnAα and CnAβ2 lacking the auto-
inhibitory domain; CnB, calcineurin B; CsA, cyclosporine A; FoxO, Forkhead box O; 
IGF-1, insulin-like growth factor 1; NFAT, nuclear factor of activated T cells.
The online version of this article contains supplemental material.JCB • VOLUME 179 • NUMBER 6 • 2007  1206
transcripts encoding phosphatase-dead CnAβ2 or CnAβ1 pro-
tein. Interestingly, increased CnAβ1 expression was noted in 
response to the muscle-restricted overexpression of a local IGF-1 
isoform (mIGF-1), which preserved muscle integrity and en-
hanced the response to chronic degeneration in a mouse model 
of amyotrophic lateral sclerosis (ALS) (Dobrowolny et al., 2005), 
suggesting a role for CnAβ1 in satellite cell activation.
To establish a function for CnAβ1, we overexpressed the 
protein or blocked its production in muscle cell culture and found 
that, unlike other CnA variants, CnAβ1 inhibits FoxO transcrip-
tional activity independently of its phosphatase function, regu-
lates myoblast proliferation, and prevents myotube atrophy 
under starvation conditions. In addition, CnAβ1 overexpres-
sion in post-mitotic muscle enhances regeneration, reducing 
scar formation and accelerating the resolution of infl  ammation. 
The unique properties of the CnAβ1 isoform expand the spec-
trum of biological functions for calcineurins and provide new 
avenues for prevention of muscle atrophy.
Results
CnA𝗃1 is a constitutively active Cn isoform
To determine whether the absence of an autoinhibitory domain 
rendered the CnAβ1 isoform constitutively active without high 
intracellular calcium, we analyzed Cn phosphatase activity in 
HEK293 cells transfected with expression plasmids encoding 
CnAβ1, CnAβ2, or CnAβ* in which the autoinhibitory domain 
has been artifi  cially deleted. Phosphatase activity in CnAβ1-
transfected cells was as high as those expressing constitutively 
active CnAβ*, compared with cells transfected with CnAβ2 
(Fig. 1 B). Cell fractionation and subsequent analysis by Western 
blot showed that CnAβ1 is localized both in the cytoplasm and 
the nucleus in proliferating C2C12 cells, with most of the protein 
mainly localized in the cytoplasm (Fig. 1 C). Co-transfection of 
C2C12 muscle cells with CnAβ1 and an HA-NFAT expression 
vectors resulted in increased nuclear translocation of NFAT 
(Fig. 1 D). Accordingly, cotransfection of C2C12 myoblasts with dif-
ferent Cn constructs together with a Gal4-NFAT chimera and a 
Gal4-Luc reporter plasmid showed that in the absence of further 
stimulus, CnAβ1 activated NFAT in C2C12 muscle cells (Fig. 1 E; 
Fig. S1, C and D), but not in Jurkat T cells (Fig. S1 E), albeit to 
a lower degree than the truncated, constitutively active CnAβ* 
form. Interestingly, both the increased phosphatase activity and 
the activation of NFAT induced by CnAβ1 were partially resis-
tant to the action of CsA, whereas truncated Cn forms were in-
hibited by the immunosuppressant drug (Fig. 1, B and E). 
Conversely, overexpression of the VIVIT peptide, which blocks 
the interaction between Cn and NFAT, prevented the activation of 
Figure 1. CnA𝗃1 is a constitutively active Cn isoform. (A) Schematic diagram of CnAβ1 and CnAβ2 isoforms, alternative splicing variants of the CnAβ 
gene. CnAβ1 encodes an alternate C-terminal domain encoded by intronic sequences (top) whereas CnAβ2 includes a canonical autoinhibitory domain 
encoded by exons 13–14 (bottom). (B) HEK293 cells were transfected with CnA expression vectors or empty pcDNA3.1 (control), grown for 48 h in the 
absence (black bars) or presence (white bars) of 1 μg/ml CsA and Cn phosphatase activity was assayed. (C) Nuclear and cytoplasmic extracts were ana-
lyzed for the presence of CnAβ1. Anti-Stag2 and anti-PDK1, respectively show equal nuclear and cytoplasmic protein loading. (D) C2C12 myoblasts were 
transiently cotransfected with a HA-NFATc2 expression vector and pcDNA3.1-CnAβ1 or empty pcDNA3.1. After 2 d in DM, nuclear and cytoplasmic ex-
tracts were analyzed by Western blot using an anti-HA antibody. Arrow indicates increased dephosphorylated NFAT. (E) C2C12 myoblasts were transiently 
transfected with CnA expression vectors (or empty pcDNA3.1 as a control), the pGal4-Luc reporter and pGal4-NFAT-1-415 and grown in DM for 2 d. 
Where indicated, 1 μg/ml cyclosporine A (white bars) or EtOH as a vehicle (black bars) was added to the culture after transfection. (F) C2C12 myoblasts 
were transfected as in D together with a VIVIT expression plasmid or control vector and luciferase activity was analyzed. Results show fold induction over 
the control value ±SD and represent the average of at least three independent experiments. *, P < 0.05; **, P < 0.005.CNAβ1 INHIBITS FOXO AND ENHANCES MUSCLE REGENERATION • LARA-PEZZI ET AL. 1207
NFAT by all Cn forms (Fig. 1 F). Together, these results show 
that CnAβ1 is a physiological Cn form that is constitutively 
active and is partially insensitive to the action of CsA.
CnA𝗃1 expression is increased during 
skeletal muscle regeneration
We analyzed the CnA expression patterns in differentiating my-
oblasts as well as different healthy and cardiotoxin-injured mus-
cles by Northern blot and quantitative RT-PCR (qRT-PCR). All 
uninjured muscles showed high expression levels of CnAα and 
CnAβ2 and weaker expression of CnAβ1 (Fig. 2 A). Differenti-
ation of primary and C2C12 myoblasts, both of which expressed 
high CnAβ1 levels, was accompanied by a progressive increase 
in CnAβ2 and a decline in CnAβ1 levels (Fig. 2, B and C). In vivo, 
skeletal muscle regeneration in response to injury induced a 
transient rise in CnAβ1 transcripts and a concomitant decrease 
in CnAβ2 transcripts (Fig. 2, D–F). IGF-1 was able to induce 
CnAβ1 expression both in vivo, in MLC/mIGF-1 transgenic 
mice especially during recovery from muscle atrophy induced 
by sciatic denervation (Fig. 2 G), and in vitro in starving myotubes 
Figure 2. Proﬁ  le of CnA isoforms expression in skeletal muscle. (A) Expression patterns of CnAα, CnAβ2, and CnAβ1 isoforms were analyzed in different 
striated muscles by Northern blot. (B) CnA isoform expression was determined by qRT-PCR in C2C12 myoblasts incubated in growth medium (GM) or differ-
entiation medium (DM) for days indicated. Results are expressed as fold induction over the value in GM (note Log relative units ±SD). (C) Comparison of 
CnA isoform expression in proliferating primary myoblasts and adult skeletal muscle. Satellite cells were isolated using the single ﬁ  ber technique from rat 
EDL muscle, induced to proliferate in GM, and then shifted to DM for days indicated. RNA was extracted and CnAα, CnAβ2, and CnAβ1 expression ana-
lyzed by qRT-PCR. Results are expressed as fold induction over myoblasts in GM. (D) 2-mo-old wild-type mice were injured in the quadriceps muscle by 
cardiotoxin injection and allowed to recover for 2, 6, or 12 d (0, uninjured). Total muscle RNA was extracted and CnAα, CnAβ2, and CnAβ1 expression was 
determined by qRT-PCR. Results are expressed as fold induction over uninjured muscle (note Log relative units ±SD). (E and F) The switch between CnAβ1 
and CnAβ2 expression during skeletal muscle regeneration and the transient increase in CnAβ1 mRNA expression were conﬁ  rmed by Northern blot. 
(G) CnA isoform expression in denervated muscle from wild-type and MLC/mIGF-1 transgenic mice was analyzed by qRT-PCR 28 d after denervation and 
expressed as fold induction ±SD over nondenervated wild type. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.JCB • VOLUME 179 • NUMBER 6 • 2007  1208
(Fig. S2 A, available at http://www.jcb.org/cgi/content/full/jcb
.200704179/DC1). To determine whether CnAβ1 was expressed 
by muscle precursors and regenerating fi  bers or by the immune 
infi  ltrate, we analyzed its tissue distribution during skeletal 
muscle regeneration in the tibialis anterior of wild-type mice 2 
and 6 d after cardiotoxin injection. CnAβ1 was strongly ex-
pressed by muscle precursors and regenerating muscle fi  bers, 
showing a pattern similar to that of Myf5, which labels satellite 
cells and early regenerating fi  bers (Cooper et al., 1999), whereas 
uninjured fi  bers or the immune infi  ltrate (marked by anti-CD45) 
expressed little or no CnAβ1 (Fig. 3). These results implicate 
the predominant CnAβ2 isoform in skeletal muscle differentia-
tion and maturation, whereas CnAβ1 might play a role during 
myoblast proliferation and muscle regeneration.
CnA𝗃1 regulates myoblast proliferation and 
differentiation
To characterize the function of CnAβ1, we knocked down CnAβ1 
expression by transfecting proliferating C2C12 myoblasts with 
two different siRNAs specifi  c for mouse CnAβ1 (termed 132 
and 167) or a luciferase siRNA as a control (Fig. 4 A). After 48 h 
in growth medium (GM), oligonucleotide-based microarray 
analysis showed an induction of muscle differentiation-specifi  c 
gene expression in cells transfected with the CnAβ1 siRNAs 
(Fig. 4 B). The induction of the muscle differentiation pro-
gram was confi  rmed by qRT-PCR and was found to be similar 
to that obtained with cells in differentiation medium (DM) for 1 d 
(Fig. 4 C). Although the response obtained with the siRNA 167 
was weaker than that obtained with the 132 siRNA, similar-
ities in the profi  les of genes up-regulated by each of the CnAβ1 
siRNAs (P < 4.63 × 10
−138; Table S1 and S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200704179/DC1) and 
down-regulated genes (P < 4.39 × 10
−60; Table S3 and S4) in-
dicated that the observed effects were due to specifi  c knockdown 
of CnAβ1 rather than to off-target effects. Correspondingly, an in-
crease in myogenin expression was detected by Western blot after 
transfection of C2C12 cells with the CnAβ1 siRNA (Fig. 4 D).
Given that CnAβ1 knockdown results in decreased myo-
blast proliferation and increased differentiation and because 
its expression declines during myotube formation, we studied 
whether CnAβ1 could actually interfere with myoblast differ-
entiation. We generated C2C12 stable transfectants in which 
the expression of the different CnAβ isoforms is driven by the 
CMV promoter (pcDNA3.1 vector) and thus is not affected by 
differentiation. When induced to differentiate, C2C12 cells stably 
overexpressing CnAβ1 showed a mild signifi  cant increase in 
differentiation markers only at early time points (Fig. S2, B and C) 
compared with the mock transfectants. These data suggest that 
CnAβ1 may slightly accelerate the initial differentiation steps 
when artifi  cially overexpressed. It is noteworthy that this effect 
was only detected after switching C2C12 cells to differentiation 
medium and was not observed under growth conditions. A sim-
ilar dual action has been previously reported for IGF-1, which 
is able to both enhance myoblast proliferation and up-regulate 
differentiation markers once the cells have been induced to dif-
ferentiate (Engert et al., 1996; Musarò and Rosenthal, 1999). 
On the contrary, continuous overexpression of CnAβ1 had no 
impact on differentiation markers 5 d after shifting the cells to 
differentiation medium. In addition, 8 d after differentiation, myo-
tubes overexpressing CnAβ1 showed a similar diameter to that 
of myotubes bearing the expression vectors for CnAβ*, CnAβ2, 
or the parental vector alone (see Fig. 6 H; Fig. S3 C, available at 
Figure 3. CnA𝗃1 is expressed in myoblasts and regenerating skeletal muscle ﬁ  bers. 2-mo-old wild-type mice were injured in the tibialis anterior (TA) 
muscle by cardiotoxin injection and allowed to recover for 2 or 6 d. The TA muscle was extracted, ﬁ  xed, sectioned and immunostained with anti-CnAβ1, 
anti-Myf5, anti-CD45, or secondary antibody alone (Control). Arrows indicate positive cells. Bar, 100 μm.CNAβ1 INHIBITS FOXO AND ENHANCES MUSCLE REGENERATION • LARA-PEZZI ET AL. 1209
http://www.jcb.org/cgi/content/full/jcb.200704179/DC1), indi-
cating that although CnAβ1 expression is required to prevent myo-
blast differentiation, overexpression of this Cn isoform does not 
interfere with myotube differentiation.
Interestingly, CnAβ1 knockdown induced an increase in 
negative cell cycle regulators and a decrease in genes involved 
in cell cycle progression (Fig. 5, A and B). A corresponding de-
crease in BrdU incorporation (Fig. 5 C) and cell proliferation 
(Fig. 5 D) was observed after CnAβ1, but not CnAβ2, knock-
down, accompanied by a decrease in the percentage of cells in 
the G2/M phase of the cell cycle and an increase in G1 (Fig. 5 E), 
indicating that the CnAβ1 isoform is necessary for cell cycle 
progression. C2C12 stable transfectants overexpressing CnAβ1 
showed only a modest increase in BrdU incorporation (Fig. 5 F). 
Together, these results suggest that CnAβ1 is required for myo-
blast proliferation and that CnAβ1 knockdown results in exit 
from the cell cycle and subsequent myoblast differentiation.
CnA𝗃1 inhibits FoxO transcription factors
Many of the negative cell cycle regulators induced by CnAβ1 in-
hibition, such as p21, Rbl2, and Gadd45a, are known to be regu-
lated by the FoxO family of transcription factors (Furukawa-Hibi 
et al., 2002; Kops et al., 2002; Tran et al., 2002; Seoane et al., 
2004). We observed that additional FoxO target genes were 
induced after CnAβ1 knockdown as observed by microarray 
(Fig. 6 A) and qRT-PCR analysis (Fig. 6 B), including increased 
expression of atrogenes Murf1 and MAFbx/Atrogin that are 
known to mediate FoxO-induced muscle atrophy (Sandri et al., 
2004; Stitt et al., 2004). Inhibition of CnAβ1 by siRNA abro-
gated FoxO3a phosphorylation at Ser253, (Fig. 6 C) and also 
resulted in defective PDK1 and Akt phosphorylation, without af-
fecting mTOR or Erk, suggesting that CnAβ1 is required for the 
activation of the PDK1-Akt-FoxO phosphorylation cascade that 
leads to FoxO inhibition. An increase in p38 phosphorylation was 
observed that is likely to be a direct consequence of C2C12 differ-
entiation (Perdiguero et al., 2007), rather than a direct target of 
CnAβ1 knockdown. Moreover, overexpression of CnAβ1, but 
not CnAβ2 or the constitutively active CnAβ*, in C2C12 cells 
inhibited FoxO nuclear localization (Fig. 6 D; Fig. S3 A) and 
the activity of a FoxO-dependent luciferase reporter (Fig. 6 F), 
whereas transfection of C2C12 myoblasts with the CnAβ1 siRNAs 
132 or 167 activated the reporter (Fig. 6 E). This activation was 
prevented by cotransfection with an expression plasmid for 
human CnAβ1, confi  rming the specifi  city of the response.
To determine whether FoxO inhibition by CnAβ1 can pre-
vent myotube atrophy, C2C12 stable transfectants overexpressing 
CnAβ*, CnAβ1, or CnAβ2 were differentiated into myotubes for 
8 d and then starved for 16 h. As shown in Fig. 6 H and Fig. S3 C, 
starvation caused a 35–40% decrease in myotube diameter that was 
prevented by CnAβ1, but not by CnAβ* or CnAβ2. Accordingly, 
CnAβ1 overexpression repressed FoxO in starving cells (Fig. 6 F) 
and CnAβ1 knockdown blocked repression of FoxO by IGF-1 
(Fig. 6 G). However, CnAβ1 had no effect on a constitutively 
active FoxO3a-A3 mutant lacking the three Akt/SGK phosphory-
lation sites (Nakae et al., 2000) (Fig. 6 F), which also renders the 
transcription factor insensitive to IGF-1 (Zheng et al., 2000; Brunet 
et al., 2001). Because IGF-1 inhibits FoxO-regulated atrogenes 
(Sandri et al., 2004; Stitt et al., 2004; and Fig. S3 B) and CnAβ1 
expression is induced by IGF-1 in atrophied and regenerating 
muscle (Dobrowolny et al., 2005; Fig. 2 G, Fig. S2 A), IGF-1 and 
CnAβ1 may share common pathways for the inhibition of FoxO 
and FoxO-regulated processes. Interestingly, inhibition of FoxO 
activity and nuclear localization by CnAβ1 did not require a func-
tional phosphatase domain because a phosphatase-dead CnAβ1 
mutant (CnAβ1mut) also reduced FoxO nuclear localization and 
activation (Fig. 6, D and F). In addition, NFAT-regulated genes 
were only slightly affected by CnAβ1 knockdown in myoblasts 
(Fig. 6 B). These results suggest that the main role of CnAβ1 in 
proliferating myoblasts is to inhibit FoxO, allowing cell prolifera-
tion and preventing differentiation, rather than to activate NFAT, 
which is involved in myoblast differentiation (Delling et al., 2000) 
after CnAβ1 expression has been shut down.
Figure 4. CnA𝗃1 knock-down results in myoblast differentiation. 
(A) C2C12 myoblasts were transfected with CnAβ1-speciﬁ  c siRNAs 132 (black 
bars) and 167 (gray bars) or a control siRNA, grown for 48 h in growth 
medium (GM), and the expression of CnAβ1 was assayed by microarray 
and qRT-PCR. (B and C) RNA was extracted from myoblasts transfected 
with control or CnAβ1 siRNAs and subjected to microarray (B) or qRT-PCR 
(C) analysis. Comparison with untransfected cells differentiated for 24 h 
(DM 1d) is shown. Gene expression is represented as fold induction ±SD 
(note Log. relative units) of values from cells transfected with each CnAβ1 
siRNA over those transfected with control siRNA. (D) C2C12 myoblasts 
were transfected with control or CnAβ1 siRNA and the expression of 
CnAβ1, CnAβ2, and myogenin was analyzed by Western blot. *, P < 
0.05; **, P < 0.005; ***, P < 0.0005.JCB • VOLUME 179 • NUMBER 6 • 2007  1210
CnA𝗃1 enhances skeletal muscle 
regeneration
Given that CnAβ1 expression is induced by mIGF-1 during skel-
etal muscle regeneration (Fig. 2 G; Dobrowolny et al., 2005) and is 
necessary for the activation of the PDK1/Akt signaling pathway 
that leads to FoxO inhibition, we explored whether CnAβ1 shared 
some of the regenerative abilities of mIGF-1. We generated 
MLC/CnAβ1 transgenic mice, expressing CnAβ1 in a skeletal 
muscle-specifi  c, post-mitotic restricted fashion using a myosin 
light chain (MLC)1/3 expression cassette (Fig. 7 A), and MLC/
CnAα transgenic mice expressing a full-length CnAα construct, 
including the autoinhibitory domain, as control. DNA microarray-
based transcript expression profi  ling of the quadriceps muscles 
of wild-type, MLC/CnAα, and MLC/CnAβ1 uninjured mice 
at 2 mo of age revealed an induction of slow fi  ber-associated 
genes including β-myosin heavy chain (Myh7), myosin light 
chains (Myl3, Myl2), troponins (Tnni1, Tnnt1), tropomyosins 
(Tpm3), and Serca2a in MLC/CnAβ1 mice compared with wild-
type and MLC/CnAα mice (Table S4). Quantitative RT-PCR 
corroborated the up-regulation of TnI1 (slow) and slight de-
crease of TnI2 (fast) expression in MLC/CnAβ1 mice compared 
with wild-type and MLC/CnAα (Fig. 7 B). Moreover, NADH-
tetrazolium reductase staining of EDL sections from wild-type 
and MLC/CnAβ1 mice showed a signifi  cant increase in the 
number of slow fi  bers in mice overexpressing CnAβ1 (Fig. 7, 
C and D). and similar results were obtained when the amount of 
slow MHC-expressing fi  bers was determined by immunohisto-
chemistry (Fig. 7, E and F).
To determine whether supplemental CnAβ1 transgene 
  expression contributed to muscle regeneration, we injected car-
diotoxin into the tibialis anterior (TA) and quadriceps muscles 
of wild-type (WT), MLC/CnAα, and MLC/CnAβ1 mice and 
allowed regeneration to proceed for 2, 6, or 12 d (Musarò et al., 
2001). Both wild-type and MLC/CnAβ1 mice presented similar 
muscle damage 2 d after the injury, suggesting analogous sus-
ceptibility to the toxin (Fig. 8 A). In contrast, regenerating TA 
muscle from MLC/CnAβ1 mice 12 d after CTX injury con-
tained larger myotubes with centralized nuclei and less extra-
cellular matrix accumulation when compared with regenerating 
wild-type muscle (Fig. 8 A). The enhanced regenerative capacity 
induced by CnAβ1 was also refl  ected in the increased mean 
cross-sectional area (CSA) of the MLC/CnAβ1 myofi  bers 12 d 
after CTX injection, compared with those of wild-typeT mice 
(2.1-fold increase; Fig. 8 B). Interestingly, an increase in the 
satellite cell markers Myf5 and Pax7 was observed 6 d after the 
injury in MLC/CnAβ1 mice compared with wild type (Fig. 8, 
C and D), paralleling the response obtained in response to 
IGF-1 in a murine model of ALS (Dobrowolny et al., 2005). 
Unlike mIGF-1 (Musarò et al., 2001), CnAβ1 overexpression 
did not result in muscle hypertrophy, indicating that the regen-
erative and hypertrophic responses induced by mIGF-1 in skeletal 
muscle may be driven by different mechanisms.
Figure 5. CnA𝗃1 knock-down reduces myoblast pro-
liferation. (A and B) C2C12 myoblasts were transfected 
with control or CnAβ1 siRNAs 132 and 167, grown 
for 48 h, and mRNA expression was analyzed by 
microarray (A) and qRT-PCR (B). Gene expression is 
shown as fold induction ±SD (note Log. relative units) 
of values from cells transfected with each CnAβ1 
siRNA over those transfected with control siRNA. 
(C, D, and F) C2C12 cells transfected with the different 
siRNAs (C and D) or stably transfected with CnAβ ex-
pression plasmids (F) were allowed to grow for 48 h 
and their proliferative capacity was determined by 
BrdU incorporation (C and F) and MTT (D) assays. 
(E) C2C12 cells were transfected as in A, with control or 
CnAβ1 siRNA, grown for 48 h, and the percentage of 
cells in the G0/G1 and G2/M phases of the cell cycle 
was determined by ﬂ   ow cytometry after staining the 
cells with propidium iodide. *, P < 0.05; **, P < 
0.005; ***, P < 0.0005.CNAβ1 INHIBITS FOXO AND ENHANCES MUSCLE REGENERATION • LARA-PEZZI ET AL. 1211
To elucidate the mechanisms underlying the enhanced 
skeletal muscle regeneration observed in MLC/CnAβ1 mice, 
we analyzed the microarray transcription profi  les of wild-type, 
MLC/CnAβ1, and MLC/CnAα quadriceps during the regen-
eration process. In CTX-injured wild-type muscle, induction of 
genes involved in the immune response included chemotaxis 
and macrophage-specifi  c genes, and extracellular matrix pro-
duction, especially collagen, paralleled by a strong decrease in 
the expression of genes associated with the mitochondria and
energy production, likely refl  ecting myocyte necrosis (Fig. 9 A; 
Table S5, available at http://www.jcb.org/cgi/content/full/
jcb.200704179/DC1). In contrast, MLC/CnAβ1 muscle signifi  -
cantly decreased the expression of genes associated with both 
immune response and scar formation 12 d after the muscle injury 
compared with wild-type mice and showed a faster recovery 
of mitochondrial gene expression (Fig. 9 A). Quantitative RT-
PCR analysis of the chemokine macrophage chemoattractant 
protein (MCP-1), the profi  brotic factor TGF-β1, and collagen I 
confi  rmed the results seen with the microarrays, with a signifi  -
cant decrease of these factors in MLC/CnAβ1 mice at both 6 
and 12 d after the injury, and showed no differences between 
the two genotypes 2 d after CTX injection (Fig. 9 B), confi  rm-
ing that wild-type and MLC/CnAβ1 mice were equally suscep-
tible to the action of cardiotoxin. We quantifi  ed the presence 
of different leukocyte populations during muscle regeneration 
by qRT-PCR and found decreased expression of the monocyte/
macrophage marker CD14 in MLC/CnAβ1 mice compared 
with wild type 6 and 12 d after the injury (Fig. S4 A, available at 
Figure 6. CnA𝗃1 inhibits FoxO. (A and B) C2C12 myoblasts were transfected with CnAβ1 siRNAs 132 (black bars) and 167 (gray bars) or a control siRNA 
and grown for 48 h in GM. RNA was analyzed by microarray (A) and qRT-PCR (B) for induction of FoxO (A and B) or NFAT (B) targets and expressed as 
fold induction ±SD of values from cells transfected with each CnAβ1 siRNA over those transfected with control siRNA. (C) C2C12 cells were transfected 
with CnAβ1 siRNA 132 or a control siRNA and the phosphorylation status of Foxo3a, PDK1, Akt, mTOR, Erk, and p38 was analyzed by Western blot. 
(D) C2C12 myoblasts were transfected with pGFP-FoxO3a and CnA expression vectors and the number of cells with preferentially nuclear GFP-Foxo3a 
  localization was quantiﬁ  ed. (E–G) C2C12 myoblasts were cotransfected with the p6xDBE-Luc reporter and the following vectors and/or siRNAs: (E) control or 
CnAβ1 siRNAs 132 and 167, together with CnAβ1 (black bars) or control (white bars) expression plasmids; (F) control or different CnA expression vectors; 
(G) control or CnAβ1 siRNA 132. (F and G) Cells were incubated for 48 h in GM (Control) or starving conditions. FoxO3a-A3 vector (F) or 25 ng/ml IGF-1 
(G) were added where indicated. Luciferase activity is expressed as fold induction ±SD over the value of empty pcDNA3.1 in GM (F) or control siRNA in 
GM (E and G). (H) C2C12 myoblasts stably transfected with the different CnAβ or empty (control) expression vectors were differentiated for 8 d and incu-
bated overnight in starving conditions. The myotube diameter was determined and expressed as relative units ±SD. *, P < 0.05; **, P < 0.005; ***, 
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http://www.jcb.org/cgi/content/full/jcb.200704179/DC1). This 
effect was paralleled by a lower degree of endothelial activation 
(Selectin P expression) and decreased expression of chemokines 
Ccl2/MCP-1 and Ccl5/Rantes in MLC/CnAβ1 mice (Fig. S4 A
and Fig. 9), together with increased expression of the anti-
infl  ammatory cytokine IL-10, an immunosuppressive mediator 
involved in the resolution of infl  ammation and the regulation of 
extracellular matrix. No signifi  cant differences were observed in 
CD4 and CD8 lymphocyte subpopulations between wild-type 
and transgenic mice, and we did not detect neutrophil markers 
by microarray or qRT-PCR at the analyzed time points. Together, 
our results suggest that the negative regulation of macrophage 
recruitment through Ccl2/MCP-1 and Ccl5/Rantes among others, 
combined with the secretion of anti-infl  ammatory mediators 
such as IL-10, may be responsible for the accelerated resolution 
of infl  ammation observed in MLC/CnAβ1 mice.
Notably, regenerating MLC/CnAα muscle showed increased 
matrix deposition, with small, separated myotubes and persistent 
presence of infi  ltrating infl  ammatory cells (Fig. 10 A) that was 
refl  ected in the smaller cross-sectional area presented by the regen-
erating myofi  bers (Fig. 10 B) and the increased collagen staining 
(Fig. 10, C and D). Microarray analysis of MLC/CnAα mice 
12 d after CTX injection revealed increased expression levels of 
genes associated with macrophage presence and extracellular 
matrix production (Fig. S5, available at http://www.jcb.org/cgi/
content/ full/jcb.200704179/DC1), indicating enhanced infl  amma-
tion and fi  brosis and supporting the impaired muscle regeneration 
displayed by these mice at this stage. In summary, the improved 
muscle regeneration associated with CnAβ1 transgene expression 
was characterized by enhanced muscle precursor expansion, 
decreased fi  brosis and infl  ammation, and faster muscle recovery, 
whereas supplemental expression of CnAα exacerbated rather 
than improved the regenerative capacity of skeletal muscle.
Discussion
This study establishes CnAβ1 as an evolutionarily conserved, 
partially CsA-insensitive Cn splicing variant that regulates cell 
Figure 7. CnA𝗃1 induces an increase in slow-type muscle ﬁ  bers. (A) Transgenic construct used in the generation of MLC/CnAβ1 and MLC/CnAα mice. 
The CnAβ1 or CnAα cDNA was placed under the control of the myosin light chain promoter and enhancer, which allows skeletal muscle-speciﬁ  c, post-
mitotic expression. Expression of CnAβ1 and CnAα transgenes in the quadriceps muscle of the transgenic mice was conﬁ  rmed by RT-PCR using speciﬁ  c 
primers for the transgene. (B) Total RNA was extracted from the quadriceps of 2-mo-old MLC/CnAβ1, MLC/CnAα, and wild-type mice and the expression of 
TnI-slow and TnI-fast was determined by qRT-PCR. Results are given as relative units referred to the values obtained in the wild-type mouse quadriceps ±SD. 
(C and E) The EDL muscle from wild-type and MLC/CnAβ1 mice was stained for NADH activity (C and D) or slow MyHC expression (E and F) and the 
number of slow ﬁ  bers per ﬁ  eld was determined (D and F). At least seven ﬁ  elds per mouse were counted. **, P < 0.01. Bar, 100 μm.CNAβ1 INHIBITS FOXO AND ENHANCES MUSCLE REGENERATION • LARA-PEZZI ET AL. 1213
proliferation and improves muscle regeneration, inhibiting FoxO 
independently of its phosphatase activity. The unexpected con-
nection between FoxO and calcineurin pathways, specifi  c for the 
CnAβ1 isoform, may have important implications for the regu-
lation of cell proliferation and for treatment of muscle wasting.
Cn activity is tightly regulated by calcium through CnB 
and calmodulin. In response to changes in intracellular calcium 
levels, the autoinhibitory domain of the enzyme is removed and 
the catalytic site is exposed (Ke and Huai, 2003). The lack of an 
autoinhibitory domain confers constitutive phosphatase activity 
and NFAT activation on the CnAβ1 variant in the absence of 
calcium increase. Although constitutive enzymatic activity has 
been previously described for artifi  cially truncated CnA forms 
(Molkentin et al., 1998), CnAβ1 is, to our knowledge, the fi  rst 
naturally occurring CnA isoform with this capacity. Contrary to 
artifi  cially truncated CnA isoforms, CnAβ1 is partially insensitive 
to the action of the immunosuppressant CsA, suggesting that 
the alternative C-terminal domain in CnAβ1 may interfere with 
the binding of the CsA–cyclophilin complex to the enzyme and 
thus prevents its inactivation. Together, these fi  ndings indicate 
that the Cn/NFAT pathway can be activated without the need for 
a rise in intracellular calcium levels by alternative splicing of 
the CnAβ gene, and that this activation is partially resistant to 
the action of CsA.
The inhibition of FoxO by CnAβ1 has important implica-
tions. The family of FoxO transcription factors control key 
physiological processes, including cell proliferation, growth, 
atrophy, metabolism, and longevity (Greer and Brunet, 2005). 
In myoblasts, FoxO is suffi  cient to induce Gadd45 expression 
and prevent cell cycle progression (Furukawa-Hibi et al., 2002). 
The abundant expression of CnAβ1 in proliferating myoblasts 
is necessary to prevent FoxO activation. Indeed, CnAβ1 knock-
down results in the induction of negative cell cycle regulators, 
blockade of cell proliferation, and subsequent myoblast dif-
ferentiation. It is noteworthy that C2C12 cells overexpressing 
CnAβ1 fuse normally into myotubes (Fig. 6 H and Fig. S4 B), 
suggesting that CnAβ1 expression is necessary for myoblast 
proliferation rather than for inhibition of differentiation. Interest-
ingly, when overexpressed in transgenic mice, CnAβ1 induces 
an increase in slow muscle fi  bers, an effect compatible with 
both FoxO inhibition and NFAT activation (Naya et al., 2000; 
Kamei et al., 2004; McCullagh et al., 2004).
FoxO factors play a crucial role in skeletal muscle at-
rophy through the induction of MAFbx/Atrogin and Murf1 
Figure 8. CnA𝗃1 enhances skeletal muscle regeneration. Wild-type and MLC/CnAβ1 mice were given ﬁ  ve cardiotoxin (CTX) injections in the tibialis ante-
rior (TA) and allowed to recover for 6 or 12 d (0, uninjured). The TA was analyzed by hematoxylin and eosin (H&E) staining (A) and the average cross-
sectional area (CSA) of the regenerating myoﬁ  bers was measured (B). Results are expressed as μm
2 ±SD. 
##, P < 10
−12 (t test; n = 2,500 ﬁ  bers (three 
mice)/mouse line). Bar, 40 μm.(C and D) RNA from the quadriceps of wild-type and MLC/CnAβ1 mice 2 and 6 d after cardiotoxin injection was analyzed 
for Myf5 (C) and Pax7 (D) expression by qRT-PCR. **, P < 0.005 compared with wild type.JCB • VOLUME 179 • NUMBER 6 • 2007  1214
(Sandri et al., 2004; Stitt et al., 2004). In response to IGF-1, 
Akt phosphorylates and inhibits FoxO, preventing Atrogin ex-
pression and muscle atrophy (Stitt et al., 2004; Schulze et al., 
2005). Interestingly, CnAβ1 is induced by IGF-1 in regenerating 
muscle and is necessary for the inhibition of FoxO activity by 
IGF-1 (Fig. 2 G, Fig. 6 G, Fig. S3 A; Dobrowolny et al., 2005). 
In addition, CnAβ1 itself is able to inhibit FoxO and prevent 
myotube atrophy induced by starvation. FoxO induction of 
MAFbx/Atrogin has recently been shown to inhibit Cn activity 
(Li et al., 2004; Ni et al., 2006); thus, the inhibition of FoxO by 
CnAβ1 might indirectly contribute to the increased Cn activity 
in CnAβ1-expressing cells. Like IGF-1, CnAβ1 needs the three 
Akt target Ser/Thr residues in FoxO in order to inhibit its activity 
and furthermore, CnAβ1 expression is necessary for PDK1 and 
Akt activation in both myoblasts and tumor cells (Fig. 4 C and 
Fig. 6 D), suggesting that IGF-1 and CnAβ1 share a common 
signaling pathway.
Supplemental expression of CnAβ1 in post-mitotic muscle 
leads to enhanced muscle regeneration. Our results suggest that 
the quicker expansion of muscle precursors combined with a faster 
resolution of both the infl  ammatory response and subsequent 
extracellular matrix deposition allows the regenerating fi  bers to 
grow more rapidly in response to CnAβ1, whereas mice over-
expressing the full-length CnAα isoform show delayed regener-
ation, with persistent infl  ammation and increased deposition 
of extracellular matrix. Interestingly, mIGF-1 enhances muscle 
regeneration in various models of muscle injury and disease by 
reducing scar formation and resolving infl  ammation faster, fa-
cilitating the recruitment of stem and progenitor cells (Musarò 
et al., 2001, 2004; Barton et al., 2002; Dobrowolny et al., 2005). 
Thus, although the role of Cn in skeletal muscle regeneration 
  remains controversial and both pro- and anti-regenerative effects 
have been reported depending on the mouse model used (Stupka 
et al., 2004; Parsons et al., 2007), the present study shows that 
Figure 9. MLC/CnA𝗃1 mice show decreased inﬂ  ammation and scar formation 12 d after muscle injury. (A) Total RNA was extracted from the quadriceps 
muscle of injured (6 and 12 d after CTX injection) and uninjured mice and subjected to microarray analysis. The average expression ±SD of the genes in 
the indicated gene ontology lists is shown in wild-type (white bars) and MLC/CnAβ1 mice (black bars), referred to the uninjured mice. (B) The expression 
of MCP-1, Collagen1α1 and TGF-β1 mRNA was analyzed in the quadriceps of wild-type (white bars) and MLC/CnAβ1 mice (black bars) at different days 
after CTX injection (0, uninjured). Results are expressed as fold induction ±SD over the values of uninjured mice. *, P < 0.05; **, P < 0.005; 
#, P < 10
−5; 
##, P < 10
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CnAβ1 is able to recapitulate the skeletal muscle regenerative re-
sponse induced by mIGF-1, probably sharing a common mecha-
nism, suggesting that this naturally occurring Cn isoform could 
prove a valuable tool in therapies aiming to counteract muscle 
atrophy and enhance regeneration.
Materials and methods
Cells, plasmids, and transfection
Cells. The murine myoblast cell line C2C12 was propagated in growth me-
dium (GM) (Dulbecco’s modiﬁ  ed Eagle’s medium [DMEM] 4.5 g/liter glu-
cose, 10% FCS, 2 mM L-glutamine, and 5 mM penicillin/streptomycin) and 
induced to differentiate in differentiation medium (DM) (growth medium, 
0% FCS, and 2% horse serum). C2C12 cells were starved by incubating in 
PBS, 1 mM CaCl2, and 1 mM MgCl2 for 16 h as described (Sandri et al., 
2004). Muscle satellite cells were isolated from rat EDL muscles using the 
single ﬁ   ber technique as previously described (Suzuki et al., 2001). 
HEK293 cells were grown in DMEM, 1 g/liter glucose, 10% FCS, 2 mM 
L-glutamine, and 5 mM penicillin/streptomycin. Jurkat T cells were grown 
in RPMI, 10% FCS, 2 mM L-glutamine, and 5 mM penicillin/streptomycin.
Plasmids. The expression vectors pcDNA3-CnAβ1, pcDNA3-
CnAβ1mut, pcDNA3-CnAβ2, pcDNA3-CnAα, pcDNA3.1-CnAα*, and 
pcDNA3.1-CnAβ* carry cDNAs of the respective CnA isoforms under the 
control of a CMV promoter (CnAα* and CnAβ* represent the artiﬁ  cially 
truncated forms of CnAα and CnAβ2; CnAβ1mut carries a D130N muta-
tion and lacks phosphatase activity). pGal4-Luc and p6xDBE-Luc express 
the luciferase reporter gene under the control of three tandem binding sites 
for the yeast transcription factor Gal4 or six tandem binding sites for the 
Caenorhabditis. elegans FoxO homologue Daf16, respectively. pGal4-NFAT 
(1–415) expresses a chimerical protein containing the Gal4 DNA-binding 
domain linked to NFAT transcription activation and regulatory domains 
(amino acids 1–415) (Luo et al., 1996). pGFP-VIVIT carries the NFAT-
speciﬁ  c inhibitory peptide VIVIT linked to GFP (15). pHA-NFAT expresses 
NFATc1 tagged with the hemagglutinin peptide. pGFP-FoxO3a and pFoxO3a-
A3 express, respectively, a GFP-FoxO3a fusion protein and a FoxO3a 
mutant in which the three Thr/Ser known to be phosphorylated by Akt and 
SGK are mutated into Ala, rendering FoxO3a insensitive to inhibition by 
Akt or IGF-1 (Dijkers et al., 2000; Potente et al., 2005).
Transfection. For NFAT activity analysis, C2C12 myoblasts were trans-
fected for 6 h with 0.5 μg of Gal4-Luc, 4 ng of the different pGal4-NFAT 
vectors along with 3 μg of pcDNA3-CnA, or empty vector, by using 10 μg 
of Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Where indicated, 1 μg of pGFP-VIVIT or the control vector pGFP was 
added. After 18 h in GM, cells were induced to differentiate in DM for 48 h 
and luciferase activity was measured. Where indicated, 10 ng/ml of cyclo-
sporin A (or equivalent volume of EtOH) was added with DM. Jurkat T cells 
were grown and transfected as described (Lara-Pezzi et al., 2004), following 
the same protocols as for C2C12 cells. For FoxO activity analysis, C2C12 cells 
were transfected with 0.25 μg of p6xDBE-Luc and either 2.5 μg Cn expression 
vectors and 0.8 μg of pFoxO3a-A3 (or pcDNA3.1 as negative control), 
Figure 10.  Overexpression of full-length CnA𝗂 iso-
form inhibits skeletal muscle regeneration. (A and C) 
Wild-type, MLC/CnAα and MLC/CnAβ1 mice were 
given ﬁ  ve CTX injections into the tibialis anterior and 
the muscle analyzed after 12 d by hematoxylin and 
eosin (H&E) or Masson trichrome (C) staining. Bar, 40 μm 
(A) or 100 μm (C). (B) The average cross-sectional 
area (CSA) of uninjured (0 d) and regenerating myo-
ﬁ  bers 12 d after CTX injection was measured and ex-
pressed as μm
2 ±SD. 
#, P < 10
−5; 
##, P < 10
−12 (t test; 
n = 2,500 ﬁ  bers (three mice)/mouse line). (D) Colla-
gen staining from C was quantiﬁ  ed and expressed as 
fold induction ±SD over the value of wild-type mice. 
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or 100 pmol of CnAβ2 or CnAβ1 siRNA. Where indicated, 25 ng/ml IGF-1 
was added to the culture for 16 h. IGF-1 and cyclosporin a (CsA) were pur-
chased from Sigma-Aldrich. Similar expression levels of all CnAβ isoforms 
after transfection were detected by qRT-PCR (Fig. S3). Stable C2C12 trans-
fectants bearing the pcDNA3.1-CnAβ1 construct or the empty pcDNA3.1 
vector were generated by selecting the cells with 0.5 mg/ml G418 after 
transfection. Two different polyclonal populations of transfectants were used 
in this study. All stable transfectants expressed similar levels of the trans-
fected CnAβ isoform, as quantiﬁ  ed by qRT-PCR (Fig. S3 B).
NADH staining, immunohistochemistry, muscle injury, and denervation
Nicotinamide adenine dinucleotide nitro-blue tetrazolium (NADH)-TR staining 
was used to differentiate fast, intermediate, and slow ﬁ  bers. Mice were killed 
by cervical dislocation and muscles were removed as fast as possible, 
embedded in Tragacanth gum (Sigma-Aldrich), and frozen in isopentane-
submerged liquid nitrogen. Frozen muscle sections (8 μm) were incubated 
in NADH-TR solution (NADH solution (Sigma-Aldrich)/nitro blue tetrazolium 
(NBT) solution (Sigma-Aldrich) [vol/vol]) for 30 min at 37°C, followed by 
three washes in ddH2O and three changes of increasing (30, 60, 90%) 
and decreasing acetone solutions (30 s each) to remove unbound NBT. 
Slides were rinsed with ddH2O and mounted with Aqua-Mount (Lerner 
Laboratories). For MyHC staining, frozen sections were cut at 16 μm, air-
dried, and ﬁ  xed in 4% PFA for 10 min on ice. Sections were then incu-
bated in PBT buffer for 15 min (0.3% Tween 20 in PBS) and blocked in 5% 
goat serum in PBT for 1 h. Primary antibodies were applied over night at 
4°C at a 1:400 dilution (Anti-Myosin Skeletal, fast, Clone MY-32; Anti-My-
osin Skeletal, slow, Clone NOQ7.5.4D; both from Sigma-Aldrich). Sam-
ples were washed three times for 15 min in PBT buffer and incubated with 
goat anti rabbit-Alexa488 secondary antibody for 45 min at RT, washed 
three times for 15 min in PBT and once in PBS containing 1× Hoechst. Im-
ages were analyzed using a microscope (Axiovert 200; Carl Zeiss, Inc.) 
with an Achroplan 10×/0.25 Ph1 ∞/− objective at room temperature, 
using 70% glycerol/ Tris-HCl as imaging medium. Pictures were captured 
using a digital camera (DXM 1200; Nikon) and acquisition software from 
Nikon (ACT-1, ver. 2). Brightness/contrast enhancement was applied to 
the whole picture at the same time using Adobe Photoshop.
For skeletal muscle regeneration experiments, tibialis anterior (TA) 
and quadriceps muscles from 2-mo MLC/CnAβ1, MLC/CnAα or wild-type 
mice were given ﬁ  ve (TA) or eight (quadriceps) 5-μl injections of 10 μM 
cardiotoxin in PBS (Musarò et al., 2001). Quadriceps muscles were col-
lected 2, 6, and 12 d (2, 5, and 10 d for the Northern blot) after cardiotoxin 
injection and snap-frozen in liquid nitrogen, and RNA was extracted. MLC/
mIGF-1 and denervation studies have been previously described (Musarò 
et al., 2001; Mourkioti et al., 2006). For histology, tibialis anterior was 
ﬁ  xed in 4% paraformaldehyde, dehydrated, and included in parafﬁ  n. Sections 
were incubated with anti-CnAβ1 (developed by the EMBL Monoclonal 
Core Facility), anti-Myf5 (Santa Cruz Biotechnology, Inc.), or anti-CD45 
(BD Biosciences) followed by the appropriate HRP-conjugated secondary 
antibody and counterstained with hematoxylin and eosin. For collagen 
staining, TA sections were stained using the Trichrome Stain (Masson) kit 
from Sigma-Aldrich, following the manufacturer’s recommendations. All im-
ages were acquired using a microscope (Axioskop; Carl Zeiss, Inc.) and a 
digital camera (DXM 1200F; Nikon) and analyzed using Nikon software 
(ACT-1, ver. 2.62). Brightness/contrast enhancement was applied to the 
whole picture at the same time using Adobe Photoshop. All experiments in-
volving animals were approved by the EMBL Animal Ethics Committee and 
were performed according to local and institutional guidelines.
siRNA, RNA isolation, cDNAs, Northern blot, and real-time PCR
The following stealth siRNAs (Invitrogen) were used: mouse CnAβ1 132 
(A  G  U  U  C  C  U  G  U  C  U  U  A  G  C  A  G  C  U  G  A  C  A  U  A  ), mouse CnAβ1 167 (G  G  G  U  A-
U  U  A  U  G  U  G  A  U  A  G  G  C  A  U  C  U  G  A  U  ), human CnAβ1 136 (G  G  U  A  G  U  G  U  A  U  U-
A  G  C  U  A  G  U  G  U  C  U  C  A  U  ), human CnAβ1 247 (G  A  U  A  U  G  G  G  A  G  C  A  G  C  U  C-
A  U  A  U  C  A  U  A  A  ), mouse and human CnAβ2 (G  A  C  U  G  G  C  A  A  C  C  A  U  A  G  U  G-
C  C  C  A  G  U  G  A  ), and Luciferase, used as a negative control (G  C  C  C  G  C  G  A  A-
C  G  A  G  A  U  U  U  A  U  A  A  U  G  A  A  ). Total RNA was extracted from snap-frozen tissue 
or cell cultures by using Trizol (Sigma-Aldrich). 20 μg total RNA were re-
solved by agarose gel, blotted and hybridized with CnAα-, CnAβ2-, and 
CnAβ1-speciﬁ  c probes. For real-time PCR analysis, cDNA was generated 
using a Roche kit from 2 μg of total RNA in a 40-μl volume. Human tumor 
cDNA (matching tumor and nontumor samples from the same patient) from 
ﬁ  ve lung tumor patients and ﬁ  ve colon tumor patients was purchased from 
Clontech Laboratories, Inc.
A total of 2 μl of the cDNA reaction were ampliﬁ  ed by PCR in dupli-
cate by using either Taqman probes (Applied Biosystems) or a SYBR green 
kit (Finnzymes), and the following annealing temperatures and primers: 
CnAβ1, 57° (fwd-A  G  A  A  G  G  T  G  A  A  G  A  C  C  A  G  T  , rev-A  G  C  A  A  G  T  T  G  C  A  T  A  A  C-
A  T  C  A  T  T  ); CnAβ2 58° (fwd-A  G  G  C  T  A  T  T  G  A  G  G  C  T  G  A  A  A  , rev-C  G  G  A  T  C  T  C  A-
G  A  A  A  G  C  A  C  ); CnAα, 57° (fwd-C  A  A  G  G  C  G  A  T  T  G  A  T  C  C  C  A  , rev-T  C  G  A  A  G  C-
A  C  C  C  T  C  T  G  T  T  A  ); CnB I (fwd 5′-A  T  G  C  A  G  A  T  A  A  G  G  A  T  G  G  A  -3′, rev 5′-G  A  AA-
G  C  A  A  A  A  G  T  G  T  T  G  G  G  -3′); ubiquitin B, 58° (fwd 5′-T  G  G  C  T  A  T  T  A  A  T  T  A  T  T  C-
G  G  T  C  T  G  C  A  T  , rev G  C  A  A  G  T  G  G  C  T  A  G  A  G  T  G  C  A  G  A  G  T  A  A  ); TnI-slow, 55° 
(fwd 5′-T  G  C  T  G  A  A  G  A  G  C  C  T  G  A  T  G  C  T  A  -3′, rev 5′-G  A  A  C  A  T  C  T  T  C  T  T  G  C  G  A-
C  C  T  T  C  -3′); TnI-fast, 55° (fwd 5′-G  A  A  G  G  A  G  A  A  C  T  A  C  C  T  G  T  C  A  G  A  -3′, rev 
5′-T  G  G  G  C  A  G  T  T  A  G  G  A  C  T  C  A  G  A  C  T  C  -3′). MAFbx/Atrogin primers have 
been previously described (Mourkioti et al., 2006). Data were normal-
ized with ubiquitin B values and expressed as fold induction over a con-
trol sample.
Microarray analysis and sequence comparison
Total RNA from the different samples was hybridized in triplicate on 
  Affymetrix mouse MG_430A2.0 or the human HG-U133A2.0 oligonucle-
otide-based arrays. Raw data were normalized and analyzed using 
GeneSpring-7.2 (Silicon Genetics). After chip normalization to the 50th 
percentile, samples were normalized to cells transfected with control siRNA 
and ANOVA statistical analysis was performed. For the analysis of cardio-
toxin-injured mice, statistically signiﬁ  cant genes were subjected to gene 
tree hierarchical clustering and lists of up-regulated and down-regulated 
genes were compared with annotated gene ontology lists, choosing those 
lists with at least 10 genes in common and a P value < 10
−11 (wild type) 
or P < 10
−7 (MLC-CnAβ1). The average of the relative gene expression 
variation of the genes in these lists (mitochondria, 661 genes; immune 
  response, 200 genes; macrophage-associated, 6 genes; extracellular ma-
trix, 164 genes; collagen, 26 genes; complete gene lists available upon 
request) in the different experimental conditions was calculated and ex-
pressed as fold induction over the value of the uninjured wild-type mice.
Intronic sequences obtained from Ensemble (www.ensemble.org) 
were translated using the Expasy translation engine (www.expasy.org) and 
compared using ClustalW (www.ebi.ac.uk/clustalw).
Proliferation analysis
Cell proliferation was quantiﬁ   ed using the MTT cell proliferation assay 
(Sigma-Aldrich) 0 and 48 h after cell transfection. BrdU incorporation was 
measured 0 and 48 h after transfection with the different siRNAs by using 
the BrdU ELISA Assay Kit (Roche) following the manufacturer’s instructions. 
Cell cycle analysis was performed 48 h after transfection of C2C12 myo-
blasts with the different siRNAs by ﬁ  xing the cells in 70% ethanol for 2 h, 
staining the nuclei with 20 μg/ml propidium iodide and analyzing them in 
a ﬂ  ow cytometer (Beckman Coulter).
Western blots and ELISA
Western blots were performed as previously described (Lara-Pezzi et al., 
2002). Antibodies against CnAβ1 were generated using the C  G  M  D  W  G  T-
P  H  S  F  A  N  N  S  H  N  A   peptide as an immunogen. Antibodies against CnAβ2, 
myogenin, and p53 were obtained from Santa Cruz Biotechnology, Inc. 
and used at 1 μg/ml. Anti-phospho-Ser253-FoxO3a, anti-FoxO3a, anti-
phospho-PDK1, anti-PDK1, anti-phospho-Thr308-Akt, anti-Akt anti-phospho-
mTOR, anti-mTOR, anti-phospho-Erk, anti-Erk(p42), anti-phospho-p38, and 
anti-p38 were purchased from Cell Signaling Technology. Anti-Stag2 was 
a gift of Dr. José Luis Barbero (CNB, Madrid, Spain; Prieto et al., 2002). 
Anti-HA was purchased from Roche. Secondary HRP-conjugated anti–rabbit 
and anti–mouse antibodies were obtained from GE Healthcare and used 
at a 1:3,000 dilution. Peroxydase activity was visualized using a Super-
Signal kit (Thermo Fisher Scientiﬁ  c). Films were scanned and brightness/
contrast was enhanced for the whole picture following a dust and scratches 
ﬁ  lter using Adobe Photoshop. The Cn activity was assayed by ELISA 
  (BIOMOL International, L.P.) in extracts of 293 cells transfected with 2.5 μg of 
different Cn-expression vectors or empty pcDNA3.1 as a control. Cn activ-
ity was determined in the presence or absence of EGTA and okadaic acid 
following the manufacturer’s instructions and the results expressed as the 
phosphatase activity obtained in the presence of okadaic acid minus the 
activity obtained in the presence of EGTA.
Online supplemental material
Fig. S1 includes a schematic representation of the functional domains of 
the different Cn isoforms and shows that the C-terminal region of CnAβ1 
is conserved among vertebrates. It also illustrates how the Gal4 luciferase 
system works and shows that both CnAβ1 and the artiﬁ  cially truncated 
CnAβ* form are constitutively able to activate NFAT-dependent transcrip-
tion in C2C12 myoblasts, but not in Jurkat. Fig. S2 shows that IGF-1 induces CNAβ1 INHIBITS FOXO AND ENHANCES MUSCLE REGENERATION • LARA-PEZZI ET AL. 1217
CnAβ1 expression in starving myotubes and shares some targets with 
CnAβ1. It also demonstrates that C2C12 stable transfectants overexpress 
the different CnAβ isoforms at similar levels and that CnAβ1 does not 
interfere with myotube differentiation. Fig. S3 shows GFP-FoxO3a lo-
calization in the presence of the different CnAβ isoforms and includes 
phase-contrast pictures corresponding to Fig. 6 H. Fig. S4 analyzes the 
presence of different leukocyte subpopulations and the expression of 
FoxO and NFATc targets in regenerating muscle in both wild-type and 
MLC/CnAβ1 mice. Fig. S5 shows microarray analysis of regenerating 
muscle in wild-type, MLC/CnAβ1, and MLC/CnAα mice. The supplemen-
tary tables include lists of genes generated during the different microarray 
analyses. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200704179/DC1.
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